REMS are developed based on data from clinical trials and other sources that indicate a significant risk associated with a drug. The FDA works with the drug manufacturer to create a REMS program tailored to the specific risk profile of the drug. This collaborative approach ensures that the REMS are both effective and feasible to implement.
